electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
electroCore (NASDAQ: ECOR) announced on October 3, 2025 that Jennifer Hayes will join the company as Vice President, Human Resources and Employee Success, effective October 6, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
electroCore (NASDAQ: ECOR) announced on October 3, 2025 that Jennifer Hayes will join the company as Vice President, Human Resources and Employee Success, effective October 6, 2025.
The Compensation Committee granted 10,000 restricted stock units (RSUs) as an inducement under NASDAQ Listing Rule 5635(c)(4). The RSUs vest one-third on each of the first, second and third anniversaries of the grant, subject to continued employment, and will be settled in shares of common stock upon vesting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKAWAY, N.J., Oct. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Jennifer Hayes will be joining electroCore, effective October 6, 2025, as the Company’s Vice President, Human Resources and Employee Success. The Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Ms. Hayes in connection with the commencement of her employment. The RSUs were granted as an inducement material to Ms. Hayes’ commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). One-third of the RSUs will vest on each of the first, second and third anniversaries of the date of grant, subject to Ms. Hayes’ continued employment by the Company on the applicable vesting date. Upon vesting, the RSUs shall be settled in shares of the Company’s common stock.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance. For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.